Moleculera Biosciences

Executive Summary

Moleculera Biosciences is a US-based diagnostics company pioneering precision blood-based autoantibody testing to uncover immune-mediated root causes of chronic neuropsychiatric disorders, cardiovascular conditions, and Alzheimer's disease. Founded in 2012 and headquartered in Oklahoma City, the company has developed and commercialized a suite of patented blood tests that identify autoimmune dysfunction driving patient symptoms. By enabling targeted, personalized treatments based on underlying biological mechanisms, Moleculera aims to transform care for millions suffering from conditions often misdiagnosed as purely psychiatric or idiopathic. The company's FDA-approved tests are already used by clinicians to guide therapy for conditions such as PANS/PANDAS and other autoimmune encephalopathies, with expanding research into Alzheimer's and cardiovascular disease.

Upcoming Catalysts (preview)

• H2 2025FDA clearance for Alzheimer's autoantibody panel70% success
• Q1 2025Strategic partnership with major hospital system for test adoption60% success
• H1 2025Publication of clinical validation study in peer-reviewed journal80% success